28200dkk
1,8 %
Date:2024-04-26Time:16:59:38Latest report:Q4-2023List:Mid CapTicker:GUBRA
Market Cap:4 611 mdkkEnterprise Value:4 629 mdkkNet Sales:205,0 mdkkEarnings:-44,5 mdkkEmployees:0ISIN:DK0062266474

Ratios

10-year key figure history for Gubra turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Gubra with index and moving average MA50 and MA200.

Stockprice:282,00
MA50:248,51
MA200:146,55
Price/MA200:92,4 %
RSI (14):54,7
Price/MA50:13,5 %

Description

Gubra, founded in 2008 in Denmark, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas - CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business.

Pharmaceuticals